# Pomegranate Blood Flow Meta-analysis: What the Evidence Says
Canonical: https://www.migaku.app/guides/pomegranate-blood-flow-meta-analysis-evidence-review
Category: evidence-review
Summary: Pomegranate Blood Flow Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are ra
Last reviewed: 2026-06-26
Reviewed by: Migaku Evidence Review
# Pomegranate Blood Flow Meta-analysis: What the Evidence Says

## Quick Answer

Pomegranate Blood Flow Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 2 randomized trial.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Effect of a polyphenol-rich pomegranate extract on plasma trimethylamine N-oxide levels following an oral carnitine challenge: a randomized controlled crossover trial in healthy adults. | randomized trial | 2 | 2026-05-20 | 10.3389/fnut.2026.1822840 |
| Postprandial Antihypertensive Evaluation of Microencapsulated Pomegranate Juice in Women With Mild Hypertension: A Randomized Pilot Study | randomized trial | 2 | 2026-04-02 | 10.1155/ijhy/7665540 |

## What The Sources Report

- Conclusion Under tightly controlled dietary conditions, a single dose of pomegranate extract did not reduce post-OCC TMAO responses in the overall cohort. [Haarhuis JE (2026); evidence level 2]
- Introduction Polyphenol-rich pomegranate extract has been shown to inhibit microbial trimethylamine (TMA) production from L-carnitine. [Haarhuis JE (2026); evidence level 2]
- High blood pressure (BP) is the primary risk factor for developing cardiovascular disease (CVD), which is the leading cause of death worldwide. [Betanzos-Cabrera Gabriel (2026); evidence level 2]
- Microencapsulated pomegranate juice (MPJ) improved endothelial dysfunction in women with acute coronary syndrome and in New Zealand rabbits. [Betanzos-Cabrera Gabriel (2026); evidence level 2]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For pomegranate blood flow meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Haarhuis JE (2026). Effect of a polyphenol-rich pomegranate extract on plasma trimethylamine N-oxide levels following an oral carnitine challenge: a randomized controlled crossover trial in healthy adults.. DOI: 10.3389/fnut.2026.1822840. PMCID: PMC13260717. PMID: 42293209. https://pmc.ncbi.nlm.nih.gov/articles/PMC13260717/
- Betanzos-Cabrera Gabriel (2026). Postprandial Antihypertensive Evaluation of Microencapsulated Pomegranate Juice in Women With Mild Hypertension: A Randomized Pilot Study. DOI: 10.1155/ijhy/7665540. PMCID: PMC13045256. PMID: 41938572. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13045256/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.